Who should decide? Expert Opinion on Off-Label Use
Maurie Markham, OncLive today 2/6/12. He also opines on "Who should pay?"
"...specifically in the cancer arena, where it has become remarkably common to see reports of novel strategies favorably impacting molecularly defined subsets of cancers in individual patients labeled as having untreatable malignancies, how can we be so smug as to believe we know all the answers?"